Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases

被引:70
作者
Vilalta, Anna [2 ]
Sahuquillo, Juan [1 ]
Rosell, Anna [3 ,4 ]
Poca, Maria A. [1 ]
Riveiro, Marilyn [5 ]
Montaner, Joan [3 ,4 ]
机构
[1] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona 08035, Spain
[2] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, UNINN, Barcelona 08035, Spain
[3] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurovasc Res Lab, Barcelona 08035, Spain
[4] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurovasc Unit, Barcelona 08035, Spain
[5] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurotraumatol Intens Care Unit, Barcelona 08035, Spain
关键词
blood-brain barrier; brain extracellular fluid; matrix metalloproteinases; gelatinases; microdialysis; neuroinflammation; traumatic brain injury;
D O I
10.1007/s00134-008-1056-1
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Recent experimental evidence suggests that matrix metalloproteinases (MMPs) are implicated in the pathophysiology of traumatic brain injury (TBI) by increasing blood-brain barrier permeability and exacerbating posttraumatic edema. We examined the acute profile ofMMP- 2 and MMP-9 in the plasma of patients with moderate or severe TBI and in the brain extracellular fluid (ECF). Design: Prospective observational study. Setting: Neurotraumatology intensive care unit of a tertiary university hospital. Patients: Twenty patients with moderate or severe TBI were included and three groups were used as controls: 20 patients with a mild head injury and normal CT scan, 15 moderate polytrauma patients without TBI, and 20 healthy volunteers. Interventions: Plasma samples were collected within the first 12 h and at 24 h post-injury. Simultaneous brain microdialysate and plasma samples were obtained in four moderate-severe TBI patients at additional timepoints: 48, 72, and 96 h post-TBI. Measurements and main results: Gelatinases (MMP-2 and MMP-9) were measured by gelatin zymography. A significant increase in plasma gelatinases was observed at baseline when compared with healthy volunteers in the study group. This early increase was followed by a significant decrease at 24 h post-injury. Brain microdialysis samples presented a similar time profile as plasma samples for both gelatinases. Conclusions: High levels of gelatinases were found in plasma and brain ECF in the early phase of TBI, indicating that both local and systemic trauma-induced upregulation of gelatinases in the acute phase might play an important role in the pathophysiology of TBI and could be a future therapeutic target.
引用
收藏
页码:1384 / 1392
页数:9
相关论文
共 40 条
  • [1] MMPs in the central nervous system: Where the good guys go bad
    Agrawal, Smriti M.
    Lau, Lorraine
    Yong, V. Wee
    [J]. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2008, 19 (01) : 42 - 51
  • [2] INJURY SEVERITY SCORE - METHOD FOR DESCRIBING PATIENTS WITH MULTIPLE INJURIES AND EVALUATING EMERGENCY CARE
    BAKER, SP
    ONEILL, B
    HADDON, W
    LONG, WB
    [J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1974, 14 (03): : 187 - 196
  • [3] Bullock RM, 2000, J NEUROTRAUM, V17, P449
  • [4] Regulation of matrix metalloproteinases: An overview
    Chakraborti, S
    Mandal, M
    Das, S
    Mandal, A
    Chakraborti, T
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 253 (1-2) : 269 - 285
  • [5] Multiple roles for MMPs and TIMPs in cerebral ischemia
    Cunningham, LA
    Wetzel, M
    Rosenberg, GA
    [J]. GLIA, 2005, 50 (04) : 329 - 339
  • [6] Matrix metalloproteinases in cerebrovascular diseases
    Fatar, M
    Stroick, M
    Griebe, M
    Hennerici, M
    [J]. CEREBROVASCULAR DISEASES, 2005, 20 (03) : 141 - 151
  • [7] Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain
    Gasche, Y
    Soccal, PM
    Kanemitsu, M
    Copin, JC
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2006, 11 : 1289 - 1301
  • [8] Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients - Influence of different therapies
    Horstmann, S
    Kalb, P
    Koziol, J
    Gardner, H
    Wagner, S
    [J]. STROKE, 2003, 34 (09) : 2165 - 2170
  • [9] Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO
  • [10] 2-#